Ceritinib in ALK-rearranged non-small-cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Non-Small-Cell Lung
  • Drug Resistance, Neoplasm
  • Lung Neoplasms
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Receptor Protein-Tyrosine Kinases
  • Sulfones

abstract

  • Ceritinib was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the presence of resistance mutations in ALK. (Funded by Novartis Pharmaceuticals and others; ClinicalTrials.gov number, NCT01283516.).

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4079055

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1311107

PubMed ID

  • 24670165

Additional Document Info

start page

  • 1189

end page

  • 97

volume

  • 370

number

  • 13